Nutriband CEO to Speak at Nasdaq LaB Biotech Summit, Highlighting Abuse-Deterrent Technology

Nutriband Inc. (NASDAQ: NTRB), a company focused on developing transdermal pharmaceutical products, announced that its CEO, Gareth Sheridan, will attend the inaugural Nasdaq LaB Biotech Summit on September 16, 2026, at the Nasdaq MarketSite in New York. The summit aims to bring together biotechnology executives, investors, and industry leaders for an evening of thought leadership and networking. This event provides a platform for Nutriband to showcase its innovative approach to tackling opioid abuse through its lead product, an abuse-deterrent fentanyl patch incorporating AVERSA™ technology.

The significance of this announcement lies in the context of the ongoing opioid crisis. Fentanyl is a potent synthetic opioid that is often misused, leading to addiction and overdose deaths. Nutriband's AVERSA™ technology is designed to be incorporated into any transdermal patch to prevent abuse, misuse, diversion, and accidental exposure of drugs with abuse potential. By attending the summit, Nutriband aims to engage with key stakeholders in the biotech and investment communities, potentially attracting partnerships or funding that could accelerate the development and commercialization of its product.

The Nasdaq LaB Biotech Summit is a new initiative by Nasdaq to foster innovation in the life sciences sector. For Nutriband, participation signals its commitment to being at the forefront of addressing public health challenges through technology. The company's focus on abuse-deterrent formulations aligns with regulatory and societal pressures to develop safer opioid products. The summit offers an opportunity for Nutriband to highlight how its technology can be a solution for other pharmaceutical companies looking to enhance the safety profile of their transdermal drugs.

Investors and industry observers will be watching for any announcements from the summit that could indicate progress in Nutriband's development pipeline. The company's newsroom at https://ibn.fm/NTRB provides updates on its latest developments. Additionally, the full press release about the CEO's attendance can be found at https://ibn.fm/j4F3R.

Nutriband's participation in the summit is a strategic move to raise its profile among potential partners and investors. With the ongoing emphasis on responsible opioid prescribing, the company's abuse-deterrent technology could play a crucial role in mitigating the risks associated with fentanyl patches. As the biotech sector continues to evolve, events like the Nasdaq LaB summit serve as critical venues for companies like Nutriband to advance their missions.

The company is primarily engaged in the development of a portfolio of transdermal pharmaceutical products, with its lead product being the abuse-deterrent fentanyl patch. The AVERSA™ technology is a key differentiator that could appeal to both regulators and healthcare providers. By attending the summit, Nutriband is positioning itself to capitalize on the growing demand for safer opioid alternatives.

In summary, Nutriband's CEO attendance at the Nasdaq LaB Biotech Summit is not just a networking opportunity but a strategic step to highlight the importance of abuse-deterrent technologies in combating opioid abuse. The event could pave the way for collaborations that might expedite the availability of this critical technology to patients in need.